Who Took Apoa-I Away from Obese Individuals?

Shuai Wang,Dao-quan Peng
DOI: https://doi.org/10.1016/j.ijcard.2016.03.106
IF: 4.039
2016-01-01
International Journal of Cardiology
Abstract:Apolipoprotein A-I (apoA-I), the major protein component of high-density lipoprotein (HDL), is a key marker of HDL-cholesterol levels. Studies have shown that the level of apoA-I is more closely correlated with the reduced risk of atherosclerosis than other markers of HDL. As early as 1980s, previous epidemiologic studies had found a significant inverse correlation between obesity and plasma apoA-I level in adults of both sexes. In Framingham Offspring Study, plasma apoA-I levels significantly declined in a linear fashion with increasing BMI (ranging from <21 to ≥30 kg/m2) [ [1] Lamon-Fava S. Wilson P.W. Schaefer E.J. Impact of body mass index on coronary heart disease risk factors in men and women. The Framingham Offspring Study. Arterioscler. Thromb. Vasc. Biol. 1996; 16: 1509-1515 Crossref PubMed Scopus (267) Google Scholar ]. Besides, studies that had used direct measurement to evaluate fat distribution by computed tomography had shown that abdominal fat deposition and abdominal adipocyte hypertrophy closely correlated negatively with plasma apoA-I [ [2] Nicklas B.J. Penninx B.W. Ryan A.S. Berman D.M. Lynch N.A. Dennis K.E. Visceral adipose tissue cutoffs associated with metabolic risk factors for coronary heart disease in women. Diabetes Care. 2003; 26: 1413-1420 Crossref PubMed Scopus (138) Google Scholar ]. The reduced apoA-I levels associated with obesity may contribute to the increased risk of CAD in obese subjects. The question is what's the mechanism underlying the observed low apoA-I concentration in obese subjects.
What problem does this paper attempt to address?